Michael Smylie, MD

Articles by Michael Smylie, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,Michael Smylie, MD,John R. Mackey, MD,Dick Au, MD,Evelyn Sansregret, MD,Daniel Noel, MD,Alexander H. Paterson, MD,Taher Al-tweigeri, MD,Fernad Delorme, MD,Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Latest Updated Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer
August 1st 1997

Michael Smylie, MD

Articles by Michael Smylie, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC

Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC

PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer

Managing Dermatologic Toxicity and Holding Therapy

Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC